Calendario

<<  Maggio 2020  >>
 Lu  Ma  Me  Gi  Ve  Sa  Do 
      1  2  3
  4  5  6  7  8  910
11121314151617
18192021222324
25262728293031

In collaborazione con:

 

 

Eventi

Al momento non ci sono eventi disponibili.

Newsletter






HEALTHCARE UTILISATION AND COSTS ASSOCIATED WITH ADDING MONTELUKAST TO CURRENT THERAPY IN PATIENTS WITH MILD TO MODERATE ASTHMA AND CO-MORBID ALLERGIC RHINITIS: PRAACTICAL STUDY.

pharmacoeconomics.gifDal Negro, Roberto (1); Piskorz, Peter (2); Vives, Roberto (3); Guilera, Magda (4); Sazonov Kocevar, Vasilisa (5); Badia, Xavier (4)

(2) Pneumology Department, Outpatients Clinic, Wotomin, Poland
(3) Allergology Department, Hospital 12 Octubre, Madrid, Spain
(4) Health Outcomes Research Europe, Barcelona, Spain
(5) Outcomes Research, Merck & Co., Inc, Whitehouse Station, New Jersey, USA


ABSTRACT

Objective: To evaluate the healthcare resource use and costs associated with adding montelukast to therapy in patients with mild to moderate persistent asthma and co-morbid seasonal allergic rhinitis whose asthma is inadequately controlled by their current asthma therapy.

Methods: A multicentre, pre-post retrospective cohort study was conducted in three European countries (Italy, Poland and Spain). Consecutive patients who were receiving inhaled corticosteroid therapy (monotherapy or combination therapy with long-acting [beta]2-adrenoceptor agonists) and who started concomitant treatment with montelukast between January 1999 and December 2002 were identified from clinical charts.

Asthma/seasonal allergic rhinitis-related concomitant medications and asthma-related outpatient care, ED visits and hospitalisations for the periods 12 months before and 12 months after montelukast initiation were recorded from patient charts and combined with country-specific published unit costs (adjusted to 2004 values). The analysis was performed from a third-party-payer perspective and thus direct healthcare resource utilisation due to asthma/seasonal allergic rhinitis and associated costs for each country were estimated.

Results: A total of 98 physicians provided data for 696 asthmatic patients with seasonal allergic rhinitis (Italy: n = 158; Poland: n = 334; and Spain: n = 204). The mean age of patients was 32.7 years, 57.5% were female and patients had asthma that was considered either mild-persistent (54.5%) or moderate-persistent (45.5%) according to the Global Initiative for Asthma classifications. The introduction of montelukast (10 mg/day daily cost range [Euro sign]0.8-1.68) was associated with increases in the total annual mean healthcare cost per patient of 11.9%, 60.4% and 5.5% for Italy, Poland and Spain, respectively. However, mean annual costs for asthma-related outpatient care, ED visits and hospitalisations dropped significantly in all three countries (Italy: from [Euro sign]805.00 to [Euro sign]281.60 [p < 0.01]; Poland: from [Euro sign]127.10 to [Euro sign]99.00 [p < 0.01]; and Spain: from [Euro sign]463.40 to [Euro sign]119.70 [p < 0.01]).

Conclusions: The addition of montelukast to therapy in patients with mild to moderate asthma and concomitant seasonal allergic rhinitis whose asthma was inadequately controlled by current asthma therapy significantly reduced the use of concomitant asthma-allergy medications, ED visits, outpatient care visits and hospitalisation. The total direct healthcare cost obtained after the addition of montelukast increased only as a result of the montelukast treatment cost.

DIRITTI RISERVATI
Pharmacoeconomics. 25(8):665-676, 2007.

Commenti

Effettuare il login per commentare gli articoli.